NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT04233021 2025-02-03
ORBITAL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT05948813 2024-11-21
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
TYK Medicines, Inc
Phase 2 Recruiting
NCT03769103 2024-10-31
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT02736513 2021-09-02
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Soroka University Medical Center
Phase 2 Unknown